The landscape of modern precision medicine is increasingly reliant on the accuracy and integrity of molecular diagnostics. At the forefront…
Read More
Biohaven and Ono Pharmaceutical Forge Up to $100m Licensing Deal for Advanced IgG Degrader Portfolio in Asia
The global biopharmaceutical landscape witnessed a significant strategic alliance as Biohaven Ltd. announced a landmark licensing and regional partnership agreement…
Read More
Shionogi Expands Rare Disease Portfolio With $2 Billion Acquisition of IntraBio and Flagship Drug Aqneursa
Japanese pharmaceutical major Shionogi has announced a definitive agreement to acquire IntraBio in a multibillion-dollar transaction valued at $2 billion.…
Read More
Novo Nordisk Expands Cardiometabolic Portfolio With $2.3bn Hengrui Licensing Deal for Once-Weekly Oral GLP-1/GIP Agonist HRS-1596
In a strategic move to cement its leadership in the booming cardiometabolic therapeutics market, Danish pharmaceutical titan Novo Nordisk has…
Read More
5 Real-World SQL Projects to Build Your Data Portfolio
SQL remains a cornerstone skill for professionals across the data landscape, from data analysts and scientists to business intelligence specialists…
Read More
Anixa Biosciences Secures Key Patent for Breast Cancer Vaccine Technology in South Korea, Expanding Global Intellectual Property Portfolio
Anixa Biosciences has achieved a significant milestone in its quest to develop a preventive vaccine for breast cancer, securing a…
Read More
Angelini Pharma Acquires Catalyst Pharmaceuticals for $4.1 Billion to Bolster Rare Disease and Brain Health Portfolio
Angelini Pharma, a prominent player in the pharmaceutical sector, has announced a definitive agreement to acquire Catalyst Pharmaceuticals for an…
Read More
Gilead Sciences Reports Robust Q1 2026 Performance Driven by Strong HIV Portfolio and Promising PrEP Launches
Gilead Sciences has commenced 2026 with a demonstrably strong first quarter, reporting significant revenue growth primarily fueled by its leading…
Read More
Chiesi Acquires KalVista Pharmaceuticals for $1.9 Billion, Bolstering Rare Disease Portfolio with On-Demand HAE Treatment
In a landmark move that marks the largest acquisition in its 90-year history, Italian pharmaceutical giant Chiesi has agreed to…
Read More
BioMarin Pharmaceutical Finalizes $4.8 Billion Acquisition of Amicus Therapeutics, Bolstering Rare Disease Portfolio
BioMarin Pharmaceutical has officially concluded its substantial acquisition of Amicus Therapeutics, a move that promises to significantly expand BioMarin’s footprint…
Read More
